- Home
- KROS vs AUTL Comparison
KROS vs AUTL Comparison
Compare KROS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- AUTL
- Stock Information
- Founded
- KROS 2015
- AUTL 2014
- Country
- KROS United States
- AUTL United Kingdom
- Employees
- KROS N/A
- AUTL N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KROS Health Care
- AUTL Health Care
- Exchange
- KROS Nasdaq
- AUTL Nasdaq
- Market Cap
- KROS 558.9M
- AUTL 625.4M
- IPO Year
- KROS 2020
- AUTL 2018
- Fundamental
- Price
- KROS $14.28
- AUTL $2.49
- Analyst Decision
- KROS Buy
- AUTL Strong Buy
- Analyst Count
- KROS 13
- AUTL 5
- Target Price
- KROS $20.63
- AUTL $9.32
- AVG Volume (30 Days)
- KROS 467.7K
- AUTL 1.7M
- Earning Date
- KROS 08-06-2025
- AUTL 08-07-2025
- Dividend Yield
- KROS N/A
- AUTL N/A
- EPS Growth
- KROS N/A
- AUTL N/A
- EPS
- KROS 0.11
- AUTL N/A
- Revenue
- KROS $214,713,000.00
- AUTL $9,011,000.00
- Revenue This Year
- KROS $5,006.76
- AUTL $461.76
- Revenue Next Year
- KROS N/A
- AUTL $112.66
- P/E Ratio
- KROS $131.15
- AUTL N/A
- Revenue Growth
- KROS 91657.70
- AUTL N/A
- 52 Week Low
- KROS $9.12
- AUTL $1.11
- 52 Week High
- KROS $72.37
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- KROS 63.37
- AUTL 73.68
- Support Level
- KROS $13.26
- AUTL $2.40
- Resistance Level
- KROS $14.83
- AUTL $2.53
- Average True Range (ATR)
- KROS 0.40
- AUTL 0.13
- MACD
- KROS 0.13
- AUTL 0.01
- Stochastic Oscillator
- KROS 79.87
- AUTL 89.80
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.